+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic



BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic



Journal of Clinical Oncology 20(4): 994-999



To determine the prevalence of BRCA1 and BRCA2 mutations in families identified in a breast cancer risk evaluation clinic. One hundred sixty-four families seeking breast cancer risk evaluation were screened for coding region mutations in BRCA1 and BRCA2 by conformation-sensitive gel electrophoresis and DNA sequencing. Mutations were identified in 37 families (22.6%); 28 (17.1%) had BRCA1 mutations and nine (5.5%) had BRCA2 mutations. The Ashkenazi Jewish founder mutations 185delAG and 5382insC (BRCA1) were found in 10 families (6.1%). However, 6174delT (BRCA2) was found in only one family (0.6%) despite estimates of equal frequency in the Ashkenazi population. In contrast to other series, the average age of breast cancer diagnosis was earlier in BRCA2 mutation carriers (32.1 years) than in women with BRCA1 mutations (37.6 years, P =.028). BRCA1 mutations were detected in 20 (45.5%) of 44 families with ovarian cancer and 12 (75%) of 16 families with both breast and ovarian cancer in a single individual. Significantly fewer BRCA2 mutations (two [4.5%] of 44) were detected in families with ovarian cancer (P =.01). Eight families had male breast cancer; one had a BRCA1 mutation and three had BRCA2 mutations. BRCA1 mutations were three times more prevalent than BRCA2 mutations. Breast cancer diagnosis before 50 years of age, ovarian cancer, breast and ovarian cancer in a single individual, and male breast cancer were all significantly more common in families with BRCA1 and BRCA2 mutations, but none of these factors distinguished between BRCA1 and BRCA2 mutations. Evidence for reduced breast cancer penetrance associated with the BRCA2 mutation 6174delT was noted.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045344585

Download citation: RISBibTeXText

PMID: 11844822

DOI: 10.1200/jco.2002.20.4.994


Related references

Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status. Breast Cancer Research and Treatment 127(3): 819-829, 2011

Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation. Clinical Genetics 84(1): 43-46, 2014

Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families. Breast Cancer Research and Treatment 130(3): 1057-1061, 2012

Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. Journal of Clinical Oncology 19(8): 2247-2253, 2001

Overestimation of BRCA1/BRCA2 mutation risk by women with familial breast/ovarian cancer. Breast Cancer Research & Treatment 46(1): 39, 1997

The frequency and outcome of breast cancer risk-reducing surgery in Finnish BRCA1 and BRCA2 mutation carriers. Scandinavian Journal of Surgery 103(1): 34-40, 2014

BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1. British Journal of Cancer 78(11): 1417-1420, 1998

Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation. European Journal of Surgical Oncology 28(6): 627-632, 2002

Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute 109(7), 2017

Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. International Journal of Epidemiology 2018, 2018

Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment 151(2): 435-441, 2016

Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clinical Cancer Research 9(10 Pt 1): 3606-3614, 2003

Cosmetic outcome of prophylactic mastectomy followed by immediate breast reconstruction using a subpectorally placed silicone prosthesis in women at risk of hereditary breast cancer or with a proven BRCA1 or BRCA2 germ-line mutation. EJC Supplements 2(3): 167, 2004

Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2. Journal of Medical Genetics 50(6): 368-372, 2013

Increased rate of phenocopies in all age groups in BRCA1/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers. Cancer Epidemiology, Biomarkers and Prevention 22(12): 2269-2276, 2014